S. Slavin

J. Vose, J. Winter, P. Hari, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins

J. Uhr, E. Vitetta, S. Slavin, 1982, The Journal of experimental medicine.

Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial.

M. Muszkat, A. Bloom, M. Aker, 2004, Clinical therapeutics.

Intra‐arterial catheter directed therapy for severe graft‐versus‐host disease

A. Nagler, A. Bloom, M. Aker, 2002, British journal of haematology.

Development of Secondary Anaplastic Oligoastrocytoma after Matched Unrelated Bone Marrow Transplantation in a Child with Acute Myeloid Leukemia

A. Nagler, S. Panigrahi, S. Slavin, 2003, Acta Haematologica.

Allogeneic Cell‐Mediated and Cytokine‐Activated Immunotherapy for Malignant Lymphoma at the Stage of Minimal Residual Disease After Autologous Stem Cell Transplantation

A. Nagler, J. Kapelushnik, C. Brautbar, 1998, Journal of immunotherapy.

Low molecular weight heparin for hickman catheter‐induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation

A. Nagler, A. Eldor, S. Slavin, 1992, Cancer.

Bone marrow transplantation from a cadaveric donor

J. Kapelushnik, S. Slavin, M. Aker, 1998, Bone Marrow Transplantation.

Activation of the recombination activating gene 1 (RAG-1) transcript in bone marrow of senescent C57BL/6 mice by recombinant interleukin-7.

G. Friedman, A. Ben‐Yehuda, S. Slavin, 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

The oxidative status of blood cells in a murine model of graft-versus-host disease

E. Fibach, S. Slavin, L. Weiss, 2007, Annals of Hematology.

Investigations on the role of inflammatory and anti-inflammatory agents on the treatment of murine B cell leukemia by recombinant human interleukin-2.

F. Levi-Schaffer, S. Slavin, U. Vourka-Karussis, 1993, Experimental hematology.

Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.

A. Nagler, S. Slavin, R. Or, 1992, Cancer investigation.

Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated

S. Slavin, L. Weiss, S. Reich, 1992, Cancer investigation.

Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity.

M. Zeira, S. Slavin, L. Weiss, 2008, Leukemia research.

The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus.

G. Hedlund, S. Slavin, M. Rapoport, 2001, International immunopharmacology.

Transplantation of Islet Cells Across Major Histocompatibility Barriers After Total Lymphoid Irradiation and Infusion of Allogeneic Bone Marrow Cells

P. Lacy, D. Scharp, S. Slavin, 1982, Diabetes.

Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.

A. Nagler, A. Toren, S. Slavin, 1996, Transplantation.

Mesenchymal progenitor cells in red and yellow bone marrow.

S. Slavin, I. Resnick, O. Gurevitch, 2009, Folia biologica.

is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia

S. Elad, S. Slavin, B. Gesundheit, 2008 .

The hematological etiology of osteoporosis.

S. Slavin, O. Gurevitch, 2006, Medical hypotheses.

Transplantation of allogeneic or xenogeneic bone marrow within the donor stromal microenvironment.

S. Slavin, T. Prigozhina, T. Pugatsch, 1999, Transplantation.

Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome

N. Kröger, R. Brand, D. Blaise, 2007, Bone Marrow Transplantation.

Preimplantation factor (PIF) analog prevents type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice

D. Krizman, L. JeBailey, S. Slavin, 2011, Endocrine.

The Role of Proto-Oncogenes in Autoimmunity

S. Slavin, M. Rapoport, A. Mor, 1999 .

Inhibition of metastatic cell colonization in murine lungs and tumor‐induced morbidity by non‐peptidic Arg‐Gly‐Asp mimetics

R. Alon, R. Hershkoviz, L. Cahalon, 1993, International journal of cancer.

Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation.

S. Slavin, T. Prigozhina, G. Elkin, 2004, Experimental hematology.

CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells.

S. Slavin, S. Morecki, T. Prigozhina, 2003, Experimental hematology.

Total Lymphoid Irradiation Prevents Diabetes Mellitus in the Bio-Breeding/Worcester (BB/W) Rat

B. Woda, J. Mordes, A. Rossini, 1984, Diabetes.

Preimplantation Factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model

A. Vortmeyer, L. JeBailey, M. Zeira, 2012, Journal of the Neurological Sciences.

Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man

A. Nagler, M. Aker, S. Slavin, 2000, Bone Marrow Transplantation.

Activated long-term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients.

A. Nagler, S. Slavin, S. Morecki, 1997, Journal of hematotherapy.

Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate

P. Tsirigotis, S. Slavin, R. Or, 2006, Bone Marrow Transplantation.

Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy

O. Mandelboim, S. Slavin, L. Weiss, 2004, Bone Marrow Transplantation.

Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants.

F. Christiansen, C. Witt, C. Brautbar, 2005, Tissue antigens.

Nonmyeloablative bone marrow transplantation based on deletion of host-anti-donor alloreactive cells prevents autoimmune insulitis and diabetes in nonobese diabetic mice.

S. Slavin, G. Elkin, O. Gurevitch, 2002, Transplantation proceedings.

The response of cord blood megakaryocyte progenitors to IL‐3, IL‐6 and aplastic canine serum varies with gestational age

A. Nagler, A. Eldor, T. Olson, 1995, British journal of haematology.

Immunoregulation of GVHD by triggering the innate immune system with CpG

S. Slavin, S. Morecki, 2009, Expert review of hematology.

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group

H. Atkins, A. Bar-Or, M. Freedman, 2010, Multiple sclerosis.

Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major.

A. Nagler, J. Kapelushnik, M. Aker, 1998, Journal of pediatric hematology/oncology.

Reconstruction of Cartilage, Bone, and Hematopoietic Microenvironment with Demineralized Bone Matrix and Bone Marrow Cells

J. Kasir, S. Slavin, T. Prigozhina, 2003, Stem cells.

Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis

A. Gazit, E. Priel, S. Slavin, 2012, EMBO molecular medicine.

Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals.

S. Panigrahi, S. Slavin, R. Or, 2002, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes

S. Slavin, S. Morecki, A. Ackerstein, 2001, Bone Marrow Transplantation.

Cannabidiol arrests onset of autoimmune diabetes in NOD mice

I. Raz, M. Zeira, R. Mechoulam, 2008, Neuropharmacology.

Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study

N. Schmitz, S. Montoto, T. A. Lister, 2007, Leukemia.

The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders

D. Karussis, S. Slavin, B. G. Kurkalli, 2008, Clinical Neurology and Neurosurgery.

Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens.

J. Snowden, H. Heslop, B. Cohen, 2006, Arthritis and rheumatism.

Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT)

A. Ben-nun, D. Karussis, D. Lehmann, 1995, Clinical and experimental immunology.

myeloid leukemia in mice and in cell cultures Antitumor effects of human recombinant interleukin-6 on acute

R. Michalevicz, S. Slavin, M. Revel, 2011 .

Characterization of a spontaneous murine B cell leukemia (BCL1). I. Cell surface expression of IgM, IgD, Ia, and FcR.

S. Strober, E. Vitetta, S. Black, 1979, Journal of immunology.

Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization.

A. Nagler, A. Amiel, M. Fejgin, 1994, Cancer genetics and cytogenetics.

Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma

S. Slavin, S. Morecki, Y. Gelfand, 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study.

A. Nagler, J. Kapelushnik, S. Slavin, 1998, Cytokines, cellular & molecular therapy.

Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma

Y. Moshel, S. Slavin, S. Morecki, 1997, International journal of cancer.

Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma.

S. Slavin, M. Moscovitch, 1984, Journal of immunology.

Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia

A. Nagler, R. Ben-Yosef, S. Slavin, 1996, The Lancet.

Reduced-intensity conditioning or nonmyeloablative stem cell transplantation: introduction, rationale, and historic background.

S. Slavin, 2004, Seminars in oncology.

Involvement of interleukin-2 in immunologic reconstitution following bone marrow transplantation in mice.

S. Slavin, R. Or, L. Weiss, 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Optimal time interval between myeloablative whole body irradiation and reconstitution with syngeneic bone marrow graft.

S. Slavin, L. Weiss, E. Bullorsky, 1988, Bone marrow transplantation.

Hematopoietic stem cell therapy for malignant diseases

P. Tsirigotis, S. Slavin, R. Or, 2007, Annals of medicine.

Normal hematopoietic reconstitution following ASTA-Z 7557-purged grafts in the absence of in vitro CFU-GM colony growth.

A. Nagler, S. Slavin, S. Gan, 1993, Leukemia research.

Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis.

T. Ben-Hur, D. Karussis, N. Grigoriadis, 2008, Archives of neurology.

Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen

A. Nagler, D. Engelhard, S. Slavin, 2001, Bone Marrow Transplantation.

Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model

J. Kasir, M. Zeira, S. Slavin, 2005, Cancer Immunology, Immunotherapy.

Ultrastructural, cell membrane, and cytogenetic characteristics of B-cell leukemia, a murine model of chronic lymphocytic leukemia.

A. Polliack, S. Slavin, S. Morecki, 1981, Cancer research.

In-vitro T cell mediated function in patients with active rheumatoid arthritis.

S. Strober, S. Slavin, 1981, Annals of the rheumatic diseases.

The treatment of intractable rheumatoid arthritis with lymphoid irradiation.

A. Calin, Z. Fuks, R. Hoppe, 1981, International journal of radiation oncology, biology, physics.

Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma.

A. Nagler, T. Siegal, J. Kapelushnik, 1999, Leukemia & lymphoma.

Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation.

N. Schmitz, G. Dini, S. Mackinnon, 2009, Blood.

Post-hematopoietic stem cell transplantion immune-mediated cytopenias.

S. Elad, P. Tsirigotis, S. Slavin, 2009, Immunotherapy.

Recombinant Human Interleukin-6 Accelerates In-Virto Megakaryocytopoiesis and Platelet Recovery Post Autologous Peripheral Blood Stem Cell Transplantion

A. Nagler, A. Eldor, M. Pick, 1995 .

Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation

M. Labopin, D. Blaise, A. Nagler, 2008, Haematologica.

lymphoma: a double- blind placebo-controlled trial transplantation with unpurged and purged marrow in non-Hodgkin's factor after high-dose chemotherapy and autologous bone marrow Recombinant human granulocyte-macrophage colony-stimulating

L. Fouillard, P. Colombat, N. Gorin, 2013 .

Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial.

B. Coiffier, L. Fouillard, P. Colombat, 1992, Blood.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Alan M. Miller, Sonali M. Smith, R. Vij, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity allografting as first transplantation approach in relapsed/refractory grade 1-2 follicular lymphoma provides improved outcomes in long-term survivors Biol Blood Marrow Transplant

Alan M. Miller, Sonali M. Smith, R. Vij, 2015 .

Typhlitis occurring in autologous bone marrow transplantation.

A. Nagler, S. Slavin, M. Muggia-Sullam, 1992, Bone marrow transplantation.

The effect of linomide, an immunoregulator in experimental autoimmune diseases, on humoral antibody responses in mice.

I. Pecht, P. Falk, S. Slavin, 1997, Autoimmunity.

Effects of interleukin 2 on engraftment following autologous bone marrow transplantation (ABMT) in dogs.

A. Nagler, S. Slavin, R. Or, 1992, Leukemia research.

Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning.

S. Slavin, T. Prigozhina, G. Elkin, 2004, Experimental hematology.

Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts

S. Slavin, T. Prigozhina, 2004, Springer Seminars in Immunopathology.

Mini-allografts: ongoing trials in humans

R. Storb, P. Mcsweeney, R. Champlin, 2000, Bone Marrow Transplantation.

Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation.

E. Vitetta, S. Slavin, S. Morecki, 1983, Journal of immunology.

Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT).

N. Schmitz, A. Zander, A. Gratwohl, 2005, Haematologica.

Proliferative response of murine B-cell leukemia (BCL1) to poly(L-lysine).

S. Slavin, S. Morecki, Y. Flechner, 1985, Cellular immunology.

Cell mediated autoimmune granulocytopenia in a case of Felty's syndrome.

S. Slavin, M. Liang, 1980, Annals of the rheumatic diseases.

A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease.

H. Deeg, T. Fleming, J. Dipersio, 2007, Blood.

Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation

A. Nagler, M. Zeira, I. Vlodavsky, 2010, PloS one.

Heparanase prevents the development of type 1 diabetes in non‐obese diabetic mice by regulating T‐cell activation and cytokines production

O. Pappo, M. Zeira, I. Vlodavsky, 2008, Diabetes/metabolism research and reviews.

Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis.

A. Nagler, M. Zeira, I. Vlodavsky, 2010, Molecular immunology.

Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide

A. Ben-nun, D. Karussis, D. Lehmann, 1993, Annals of neurology.

Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.

A. Ben-nun, D. Karussis, D. Lehmann, 1993, The Journal of clinical investigation.

The CRST syndrome.

R. Tur-kaspa, M. Eliakim, S. Slavin, 1971, Israel journal of medical sciences.

Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients.

S. Slavin, S. Morecki, T. Prigozhina, 2004, Blood cells, molecules & diseases.

Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease.

S. Slavin, S. Morecki, 2000, Journal of hematotherapy & stem cell research.

Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin

S. Slavin, L. Weiss, 1999, Bone Marrow Transplantation.

Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation.

S. Slavin, S. Morecki, M. Weigensberg, 1985, Transplantation.

Effects of human interleukin 3, macrophage and granulocyte-macrophage colony-stimulating factor on monocyte function following autologous bone marrow transplantation.

A. Nagler, I. Fabian, S. Slavin, 1992, Leukemia research.

The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases

A. Nagler, S. Slavin, G. Váradi, 1999, Bone Marrow Transplantation.

Biological response modifiers as adjuncts to stem cell transplantation

P. Tsirigotis, S. Slavin, M. Shapira, 2006, Expert opinion on biological therapy.

Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia.

A. Nagler, M. Aker, S. Slavin, 1999, Journal of pediatric hematology/oncology.

Osteogenic growth peptide increases blood and bone marrow cellularity and enhances engraftment of bone marrow transplants in mice.

E. Berger, D. Gazit, M. Chorev, 1996, Blood.

Neutropenic enterocolitis and intestinal perforation associated with carboplatin-containing conditioning regimen for autologous bone marrow transplantation.

J. Mehta, A. Nagler, J. Kapelushnik, 1992, Acta oncologica.

Post-irradiated canine serum (PICS-J) stimulates megakaryocyte (MK) progenitors and thrombopoiesis in-vitro

A. Nagler, A. Eldor, V. Deutsch, 1996 .

Correction of enzyme deficiency in mice by allogeneic bone marrow transplantation with total lymphoid irradiation.

S. Slavin, S. Yatziv, 1980, Science.

Donor Immunization Vaccination and Transfer of Donor Immunity to Bone Marrow Transplant Recipients in the Course of Allogeneic Cell Therapy for Prevention and Treatment of Relapse

A. Nagler, S. Slavin, R. Or, 1998 .

Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients.

A. Nagler, A. Chetrit, S. Elad, 1996, Transplantation.

Adoptive transfer of immunity to hepatitis B virus after T cell–depleted allogeneic bone marrow transplantation

A. Nagler, Y. Ilan, S. Slavin, 1993, Hepatology.

Non-myeloablative stem cell transplantation for induction of host-versus-graft tolerance for adoptive immunotherapy of malignant and nonmalignant diseases and towards transplantation of organ allografts.

S. Slavin, 2002, Transplantation proceedings.

Depletion of human lymphocytes from peripheral blood and bone marrow by affinity ligands conjugated to agarose—polyacrolein microsphere beads

S. Margel, S. Slavin, L. Weiss, 1986, Applied biochemistry and biotechnology.

Single and double stranded DNA binding lymphocytes in the peripheral blood of patients with systemic lupus erythematosus and normal controls.

S. Slavin, D. Sulitzeanu, 1979, Annals of the rheumatic diseases.

Current problems and future goals in clinical bone marrow transplantation.

E. Kedar, S. Slavin, 1988, Blood reviews.

Cytokine production in Linomide-treated nod mice and the potential role of a Th (1)/Th(2) shift on autoimmune and anti-inflammatory processes.

V. Barak, M. Zeira, S. Slavin, 2002, Cytokine.

CD 44 Gene Vaccination for Insulin-Dependent Diabetes Mellitus in Non-Obese Diabetic Mice

D. Naor, S. Slavin, L. Weiss, 2022 .

Immune modulation by ionized irradiation.

Z. Tochner, S. Slavin, 1988, Current opinion in immunology.

Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.

A. Nagler, J. Kapelushnik, C. Brautbar, 1996, Blood.

Characterization of the spontaneous murine B cell leukemia (BCL1). III. Evidence for monoclonality by using an anti-idiotype antibody.

P. Isakson, S. Strober, E. Vitetta, 1979, Journal of immunology.

Purging breast cancer cells in preparation for autologous bone marrow transplantation.

S. Margel, S. Slavin, S. Morecki, 1987, Bone marrow transplantation.

IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.

S. Yarkoni, S. Slavin, N. Askenasy, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation.

S. Slavin, S. Morecki, T. Prigozhina, 2008, Experimental hematology.

Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug

T. Kalland, S. Slavin, D. Gross, 1994, Diabetologia.

Induction of mixed hematopoietic chimerism and specific transplantation tolerance to allogeneic and xenogeneic grafts by selective elimination of donor-reactive host cells following nonmyeloablative conditioning.

S. Slavin, T. Prigozhina, J. Zhu, 1997, Transplantation proceedings.

The Use of Soybean Agglutinin (SBA) for Bone Marrow (BM) Purging and Hematopoietic Progenitor Cell Enrichment in Clinical Bone Marrow Transplantation.

A. Nagler, S. Slavin, S. Morecki, 1999, Methods in molecular medicine.

Should soybean agglutinin purging be performed in breast cancer patients undergoing autologous stem cell transplantation? A retrospective analysis of 48 patients.

A. Nagler, R. Ben-Yosef, J. Kapelushnik, 1997, American journal of clinical oncology.

A controlled trial of recombinant human erythropoietin after bone marrow transplantation.

F. Mandelli, S. Burdach, J. Reiffers, 1994, Blood.

Osmotic behavior of normal and leukemic lymphocytes.

Z. Bentwich, S. Ben‐Sasson, S. Slavin, 1975, Blood.

Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils.

A. Nagler, I. Fabian, S. Slavin, 1993, Experimental hematology.

CD44 gene vaccination for insulin-dependent diabetes mellitus in non-obese diabetic mice.

D. Naor, S. Slavin, L. Weiss, 2008, The Israel Medical Association journal : IMAJ.

Superoxide dismutase inhibits radiation-induced lung injury in hamsters

Z. Tochner, S. Slavin, M. W. Conner, 2004, Lung.

Linomide, an immunomodulator that inhibits Th1 cytokine gene expression.

R. Kaempfer, S. Slavin, R. Levy, 1996, International immunology.

Herbal flavonoids inhibit the development of autoimmune diabetes in NOD mice: proposed mechanisms of action in the example of PADMA 28

I. Ginsburg, V. Barak, I. Raz, 2010 .

Split Immunity: Immune Inhibition of Rat Gliomas by Subcutaneous Exposure to Unmodified Live Tumor Cells

Z. Ram, I. Cohen, L. Eisenbach, 2011, The Journal of Immunology.

Unmodified Live Tumor Cells Gliomas by Subcutaneous Exposure to Split Immunity : Immune Inhibition of Rat

Z. Ram, I. Cohen, L. Eisenbach, 2011 .

Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone.

M. Pines, F. Levi-Schaffer, A. Nagler, 1996, The Journal of investigative dermatology.

Immunotherapy of murine leukemia following non-myeloablative conditioning with naïve or G-CSF mobilized blood or bone marrow stem cells

S. Slavin, R. Or, L. Weiss, 2004, Cancer Immunology, Immunotherapy.

Immunomodulatory effects of linomide in animals immunized with immunopathogenic retinal antigens: dissociation between different immune functions

I. Gery, M. Podgor, S. Slavin, 1997, Clinical and experimental immunology.

Conversion of red bone marrow into yellow - Cause and mechanisms.

S. Slavin, O. Gurevitch, A. Feldman, 2007, Medical hypotheses.

ASTA-Z 7557 impairs human natural killer (NK) cell activity.

A. Nagler, S. Slavin, R. Condiotti, 1996, Leukemia research.

The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors.

A. Nagler, V. Barak, S. Slavin, 1996, Leukemia research.

Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma

S. Slavin, S. Morecki, L. Yacovlev, 1998, International journal of cancer.

T-cell depletion in allogeneic bone marrow transplantation: progress and problems.

R. Storb, M. Martelli, R. Gale, 1989, Haematologica.

Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.

A. Nagler, S. Slavin, G. Váradi, 2000, Experimental hematology.

Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation.

A. Nagler, S. Slavin, R. Or, 2000, Experimental hematology.

Total lymphoid irradiation and kidney transplantation: a clinical experience.

J. Najarian, D. Sutherland, R. Simmons, 1981, Transplantation proceedings.

Fractionated Total Lymphoid Irradiation as Preparative Immunosuppression in High Risk Renal Transplantation: Clinical and Immunological Studies

D. Sutherland, R. Simmons, J. Kersey, 1982, Annals of surgery.

Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.

M. Neeman, A. Nagler, M. Pines, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Invasive fungal sinusitis in patients undergoing bone marrow transplantation.

A. Nagler, G. Rahav, J. Kapelushnik, 1993, Bone marrow transplantation.

Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities.

A. Nagler, S. Rose-John, T. Lapidot, 1997, European cytokine network.

Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors

A. Nagler, Y. Ilan, J. Kapelushnik, 1994, Clinical and experimental immunology.

Adoptive Transfer of Immunity to Hepatitis B Through Bone Marrow Transplantation from Immunized Donors

A. Nagler, Y. Ilan, D. Shouval, 1994 .

The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.

A. Nagler, S. Slavin, G. Váradi, 1999, Leukemia research.

Successful matched unrelated transplantation from a donor with idiopathic thrombocytopenic purpura (ITP)

A. Nagler, S. Slavin, R. Or, 1995, Medical oncology.

A longitudinal follow-up of salivary secretion in bone marrow transplant patients.

E. Yefenof, S. Slavin, R. Or, 1995, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.

A. Nagler, J. Kapelushnik, S. Slavin, 1996, Bone marrow transplantation.

Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice.

D. Karussis, S. Slavin, A. Ackerstein, 1995, Experimental hematology.

The use of melatonin and co-treatment with autologous or allogeneic cells as a model for control of malignant beta-cell leukemia.

I. Nir, S. Slavin, L. Weiss, 1999, Advances in experimental medicine and biology.

Total lymphoid irradiation.

S. Slavin, Shimon Slavin, 1987, Immunology today.

Review : Modulation of experimental systemic lupus erythematosus with linomide

Y. Shoenfeld, Y. Levy, J. George, 1996, Lupus.

Survey on haematopoietic stem cell transplantation for children in Europe

R. Cancedda, G. Dini, P. Veys, 2005, Bone Marrow Transplantation.

Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3-carboxamide).

S. Slavin, D. Gross, L. Weiss, 1996, Cell transplantation.

Successful Treatment of Diabetes in Nod Mice with Advanced Disease by Islet Isografts following Immunoregulation with Linomide (Quinoline-3-Carboxamide)

S. Slavin, D. Gross, L. Weiss, 1996, Cell transplantation.

allogeneic bone marrow transplantation recombinant human interleukin-2 to treat leukemia relapse after Allogeneic cell therapy with donor peripheral blood cells and

A. Nagler, J. Kapelushnik, S. Slavin, 2011 .

Graft-versus-Host Disease, the Graft-versus-Leukemia Effect, and Mixed Chimerism following Nonmyeloablative Stem Cell Transplantation

S. Slavin, 2003, International journal of hematology.

State-of-the-Art Review Donor Lymphocyte Infusion: The Use of Alloreactive and Tumor-Reactive Lymphocytes for Immunotherapy of Malignant and Nonmalignant Diseases in Conjunction with Allogeneic Stem Cell Transplantation

S. Slavin, S. Morecki, L. Weiss, 2002 .

Adoptive allogeneic cell-mediated immunotherapy and nonmyeloablative stem-cell transplantation

A. Nagler, R. Ben-Yosef, S. Slavin, 2000 .

The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.

A. Gabizon, O. Merimsky, G. Munter, 2006, Endocrine-related cancer.

Safety of retroviral gene marking with a truncated NGF receptor

A. Hagenbeek, E. Weissinger, J. Falkenburg, 2003, Nature Medicine.

Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.

A. Fischer, A. Nagler, P. Landais, 2002, Blood.

Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule

S. Slavin, S. Morecki, Y. Puyesky, 1995, Cancer Immunology, Immunotherapy.

Telomerase activity and expression in adult human mesenchymal stem cells derived from amyotrophic lateral sclerosis individuals.

A. Gazit, E. Priel, S. Slavin, 2009, Cytotherapy.

Repair of bone defect using bone marrow cells and demineralized bone matrix supplemented with polymeric materials.

D. Cohn, A. Sosnik, S. Slavin, 2010, Current stem cell research & therapy.

T-cell depleted bone marrow transplantation for plasma cell myeloma

A. Polliack, S. Slavin, R. Or, 1988, Blut.

Neurologic manifestations in patients with mixed cryoglobulinemia

O. Abramsky, S. Slavin, ODEO ABRAMSKY, 1974, Neurology.

Osteoporosis of hematologic etiology.

S. Slavin, O. Gurevitch, S. Khitrin, 2007, Experimental hematology.

Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.

Luca Biasco, Alessandro Aiuti, Alessandro Ambrosi, 2007, The Journal of clinical investigation.

Human Peripheral Blood Mononuclear Cells Incubated in Vasculogenic Conditioning Medium Dramatically Improve Ischemia/Reperfusion Acute Kidney Injury in Mice

E. Noiri, H. Mizuno, S. Hidaka, 2018, Cell transplantation.

Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent.

S. Elad, S. Slavin, R. Or, 2005, Haematologica.

Successful engraftment following allogeneic stem cell transplantation with busulfan as a

S. Elad, S. Slavin, R. Or, 2005 .

Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): A proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases

D. Karussis, S. Slavin, I. Kassis, 2008, Journal of the Neurological Sciences.

Defining the intensity of conditioning regimens: working definitions.

B. Sandmaier, D. Blaise, M. Pasquini, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tolerance to donor-type skin in the recipient of a bone marrow allograft. Treatment of skin ulcers in chronic graft-versus-host disease with skin grafts from the bone marrow donor.

D. Steiner, S. Slavin, R. Or, 1985, Transplantation.

Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside.

S. Slavin, S. Morecki, R. Or, 2004, Seminars in oncology.

T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities.

J. Klein, A. Barrett, A. Gratwohl, 2000, Blood.

Intraportal and systemic allogeneic cell therapy in a murine model of hepatic metastatic breast cancer.

S. Panigrahi, S. Slavin, S. Morecki, 2002, Cytokines, cellular & molecular therapy.

Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation

A. Nagler, D. Wolf, S. Panigrahi, 2001, Bone Marrow Transplantation.

Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

A. Mortellaro, M. Roncarolo, S. Vai, 2002, Science.

New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation.

D. Engelhard, M. Aker, S. Slavin, 1986, Israel journal of medical sciences.

Nonmyeloablative stem cell transplantation using lymphoablative rather than myeloablative conditioning in the prefludarabine era by ATG and limiting doses of cyclophosphamide

S. Slavin, R. Or, M. Shapira, 2005, Bone Marrow Transplantation.

Total lymphoid irradiation in refractory systemic lupus erythematosus.

E. Ben-Chetrit, Z. Fuks, M. Eliakim, 1986, Annals of internal medicine.

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

A. Nagler, A. Eldor, C. Brautbar, 1998, Blood.

Ganciclovir for the treatment of disseminated CMV disease without pneumonia in allogeneic T-lymphocyte depleted bone marrow transplantation.

J. Jacobs, A. Nagler, D. Engelhard, 1993, Leukemia & lymphoma.

Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.

S. Elad, M. Aker, S. Slavin, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Optimization of conditioning therapy for leukemia prior to BMT. I. Optimal synergism between cyclophosphamide and total body irradiation for eradication of murine B cell leukemia (BCL1).

S. Slavin, R. Or, L. Weiss, 1993, Bone marrow transplantation.

A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation.

S. Panigrahi, S. Slavin, S. Morecki, 2004, Experimental hematology.

T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse

S. Steinberg, A. Nagler, G. Hale, 1995, British journal of haematology.

Ciprofloxacin enhances hematopoiesis and the peritoneal neutrophil function in lethally irradiated, bone marrow-transplanted mice.

A. Nagler, I. Fabian, S. Slavin, 1994, Experimental hematology.

Functional long-term thymidine kinase suicide gene expression in human T cells using a herpesvirus saimiri vector

H. Fickenscher, S. Slavin, S. Wittmann, 2000, Gene Therapy.

Successful treatment of autoimmune disease in (NZB/NZW)F1 female mice by using fractionated total lymphoid irradiation.

S. Slavin, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Induction and mechanism of tolerance to bovine serum albumin in mice given total lymphoid irradiation (TLI).

S. Strober, S. Slavin, I. Zan‐Bar, 1978, Journal of immunology.

Total Lymphoid Irradiation for Immunosuppression

J. Najarian, D. Sutherland, R. Simmons, 1985 .

Excretion of liver antigens in the urine of patients with hepatic diseases

M. Eliakim, J. Boss, S. Slavin, 1976, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

A method for isolating pluripotent/multipotent stem cells from blood by using the pluripotent and germ-line DAZL gene as a marker.

I. Fabian, S. Slavin, J. Seligman, 2009, Stem cells and development.

Removal of breast cancer cells by soybean agglutinin in an experimental model for purging human marrow.

S. Margel, S. Slavin, S. Morecki, 1988, Cancer research.

Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours

G. Dini, I. Yaniv, U. de Giorgi, 2005, British Journal of Cancer.

Partial protection of rat parotid glands from irradiation-induced hyposalivation by manganese superoxide dismutase.

A. Nagler, R. Nagler, A. Reznick, 2000, Archives of oral biology.

Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation.

A. Nagler, S. Slavin, R. Or, 1997, Blood.

Lymphocyte subpopulations in chronic active hepatitis: increase in lymphocytes forming stable E-rosettes.

U. Galili, M. Eliakim, S. Slavin, 1975, Clinical immunology and immunopathology.

Mixed cryoglobulinemia with a monoclonal IgM component, associated with chronic liver disease.

M. Eliakim, S. Slavin, A. Zlotnick, 1972, Israel journal of medical sciences.

Clinical implications of monoclonal gammopathy in chronic liver disease

M. Eliakim, S. Slavin, I. Levij, 1974, The American Journal of Digestive Diseases.

PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION

J. Michaeli, E. Galun, G. Hale, 1985 .

Demonstration and characterization of virus released by murine B cell leukemia cells (BCL1).

M. Kotler, S. Slavin, S. Morecki, 1984, Leukemia research.

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

A. Ganser, P. Bruzzi, A. Santoro, 2009, The Lancet. Oncology.

Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.

J. Vose, P. Hari, R. Gale, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation in the elderly.

P. Tsirigotis, S. Slavin, R. Or, 2007, Critical reviews in oncology/hematology.

Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.

A. Nagler, C. Brautbar, M. Aker, 2001, Experimental hematology.

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

A. Nagler, S. Slavin, G. Váradi, 2000, Bone Marrow Transplantation.

Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination.

A. Nagler, Y. Ilan, D. Shouval, 1995, Bone marrow transplantation.

Herpesvirus saimiri pathogenicity enhanced by thymidine kinase of herpes simplex virus.

K. Mätz-Rensing, H. Fickenscher, G. Tamgüney, 2000, Virology.

Salivary immunoglobulins in recipients of bone marrow grafts. I. A longitudinal follow-up.

E. Yefenof, S. Slavin, R. Or, 1994, Bone marrow transplantation.

ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients.

P. Tsirigotis, M. Aker, S. Slavin, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment of pure red-cell aplasia following major ABO-mismatched T-cell-depleted bone marrow transplantation

S. Slavin, R. Or, E. Naparstek, 1991, Transplant international : official journal of the European Society for Organ Transplantation.

Treatment of pure red‐cell aplasia following major ABO‐mismatched T‐cell‐depleted bone marrow transplantation: Two case reports with successful response to plasmapheresis

S. Slavin, R. Or, E. Naparstek, 1991 .

Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal

T. Mikkelsen, C. Brodie, S. Finniss, 2013, Oncotarget.

Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?

R. Burt, A. Marmont, S. Slavin, 2002, International journal of hematology.

Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure?

R. Burt, A. Marmont, S. Slavin, 2002, Blood.

Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation.

A. Nagler, I. Fabian, S. Slavin, 1991, Leukemia research.

Recombinant human superoxide dismutases: production and potential therapeutical uses.

Z. Tochner, M. Fischer, S. Slavin, 1991, Free radical research communications.

Alloantigen persistence in induction and maintenance of transplantation tolerance

S. Slavin, S. Morecki, Ahmed Abulfotooh Eid, 1987, The Journal of experimental medicine.

The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation

S. Slavin, D. Ergas, L. Weiss, 2007, Bone Marrow Transplantation.

Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.

T. Mikkelsen, R. S. Goldstein, C. Brodie, 2011, Cellular signalling.

Differential effects of CD4+ and CD8+ cells on lymphocyte development from human cord blood cells in murine fetal thymus explants.

A. Nagler, A. Globerson, Z. Hagay, 1999, Experimental hematology.

Linomide, a new treatment for autoimmune diseases: the potential in type 1 diabetes.

T. Kalland, S. Slavin, D. Gross, 1993, Diabetes/metabolism reviews.

Selective elimination of alloreactivity in vitro and in vivo while sparing other T-cell-mediated immune responses

S. Slavin, S. Morecki, I. Sagiv, 2012, Bone Marrow Transplantation.

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.

A. Nagler, M. Aker, S. Slavin, 2003, Blood.

Telomere Shortening Sensitizes Cancer Cells to Selected Cytotoxic Agents: In Vitro and In Vivo Studies and Putative Mechanisms

Y. Nordenberg, B. Rinkevich, C. Rabinowitz, 2010, PloS one.

Allogeneic cell therapy for a murine mammary carcinoma.

A. Diab, S. Slavin, S. Morecki, 1998, Cancer research.

Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease

A. Nagler, J. Kapelushnik, S. Slavin, 1999, Bone Marrow Transplantation.

Visualization of immune response kinetics in full allogeneic chimeras.

S. Slavin, I. Resnick, T. Prigozhina, 2011, American journal of blood research.

Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience

G. Gahrton, G. Juliusson, S. Mackinnon, 2000 .

The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.

F. Christiansen, A. Nagler, C. Brautbar, 2004, Tissue antigens.

Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.

S. Slavin, S. Morecki, Y. Gelfand, 2004, Biology of Blood and Marrow Transplantation.

The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.

S. Slavin, L. Weiss, S. Reich, 1995, Bone marrow transplantation.

Pretransplant treatment of donors with immunomodulators to control graft-versus-host disease (GVHD) in transplant recipients.

S. Slavin, S. Morecki, Y. Gelfand, 2007, Experimental hematology.

Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.

Jeff W M Bulte, Panayiota Petrou, J. Bulte, 2010, Archives of neurology.

Bone marrow transplantation using unrelated and family related donors: the impact of HLA-C disparity.

C. Brautbar, S. Slavin, A. Bishara, 1996, Bone marrow transplantation.

Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.

P. Tsirigotis, M. Aker, S. Slavin, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens.

E. Kedar, S. Slavin, L. Weiss, 1987, Transplantation.

Bone marrow transplantation with T-cell-depleted grafts. I. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted syngeneic bone marrow grafts.

M. Ayalon, E. Kedar, S. Slavin, 1986, Transplantation.

Prevention and treatment of relapse by bone marrow transplantation.

A. Nagler, J. Kapelushnik, S. Slavin, 1993, Bone marrow transplantation.

Role of interleukin-2 in human hematological malignancies

A. Nagler, A. Toren, S. Slavin, 1995, Medical oncology.

Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.

S. Slavin, L. Weiss, S. Reich, 1999, Cytokines, cellular & molecular therapy.

Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity.

T. Bakács, R. Moss, S. Slavin, 2014, Pharmacological research.

Interleukin-3 in combination with granulocyte-macrophage-colony-stimulating factor following bone marrow transplantation in a radiation accident victim

A. Nagler, C. Brautbar, S. Slavin, 1994, Medical oncology.

Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation.

D. Wolf, S. Slavin, R. Or, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

MicroRNA-145 Is Downregulated in Glial Tumors and Regulates Glioma Cell Migration by Targeting Connective Tissue Growth Factor

T. Mikkelsen, L. Poisson, A. Toren, 2013, PloS one.

Intracranial haematomas following bone marrow transplantation

S. Slavin, R. Or, A. Lossos, 1994, Journal of Neurology.

Fibrin microbeads for isolating and growing bone marrow-derived progenitor cells capable of forming bone tissue.

A. Vexler, S. Slavin, R. Gorodetsky, 2002, Tissue engineering.

Continuous Interleukin-2 Infusion Combined with Cyclophosphamide- Based Combination Chemotherapy in the Treatment of Hemato-Oncological Malignancies

A. Nagler, R. Ben-Yosef, S. Slavin, 1998, Acta Haematologica.

Immunobiology of a Spontaneous Murine B Cell Leukemia (BCL1)

R. Warnke, S. Strober, B. Kotzin, 1979, Immunological reviews.

Secretion of idiotypic IgM by the mouse B-cell leukaemia (BCL1) occurs spontaneously in vitro and in vivo.

F. Stevenson, A. Tutt, G. Stevenson, 1985, Immunology.

Adoptive immunotherapy in conjunction with bone marrow transplantation--amplification of natural host defence mechanisms against cancer by recombinant IL-2.

S. Slavin, L. Weiss, A. Eckerstein, 1988, Natural immunity and cell growth regulation.

The role of thiotepa in autologous bone marrow transplantation for acute leukemia.

A. Nagler, S. Slavin, G. Váradi, 1998, Leukemia research.

disease induced by allogeneic lymphocytes Use of trifunctional bispecific antibodies to prevent graft-versus-host

S. Slavin, S. Morecki, H. Lindhofer, 2011 .

Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.

S. Slavin, S. Morecki, Y. Shabat, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy.

S. Slavin, S. Morecki, Y. Shabat, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.

S. Slavin, S. Morecki, P. Ruf, 2008, Experimental hematology.

Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes.

S. Slavin, S. Morecki, H. Lindhofer, 2006, Blood.

Effect of KRN7000 on induced graft-vs-host disease.

S. Panigrahi, S. Slavin, S. Morecki, 2004, Experimental hematology.

Induction of antitumor immunity by indomethacin

E. Shohami, S. Slavin, S. Morecki, 2000, Cancer Immunology, Immunotherapy.

Successful treatment of autoimmune manifestations in MRL/l and MRL/n mice using total lymphoid irradiation (TLI).

S. Slavin, M. Moscovitch, E. Rosenmann, 1983, Experimental and molecular pathology.

Long-Term Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation in First Chronic Phase of Chronic Myeloid Leukemia

M. Aker, S. Slavin, R. Or, 2006 .

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.

A. Nagler, G. Hale, H. Waldmann, 1999, Experimental hematology.

Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT).

E. Kedar, S. Slavin, R. Or, 1988, Bone Marrow Transplantation.

Enhanced marrow recovery by short preincubation of marrow allografts with human recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor.

A. Nagler, S. Slavin, R. Or, 1992, Blood.

Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation.

A. Nagler, A. Oppenheim, D. Filon, 1995, Blood.

Bone marrow transplantation in beta-thalassemia major. The Israeli experience.

D. Engelhard, E. Rachmilewitz, M. Aker, 1988, Hemoglobin.

Enhancement of hematopoietic reconstitution with recombinant cytokines: effect of rhIL-6 in combination with rhGM-CSF and rhIL-3 on unmodified or T cell-depleted bone marrow.

S. Slavin, M. Mumcuoglu, 1999, Journal of hematotherapy.

Potential use of interleukin-6 in bone marrow transplantation: effects of recombinant human interleukin-6 after syngeneic and semiallogeneic bone marrow transplantation in mice.

S. Slavin, M. Revel, T. Givon, 1994, Blood.

Induction of Tolerance to Experimental Anti‐Phospholipid Syndrome (APS) by Syngeneic Bone Marrow Cell Transplantation

Y. Shoenfeld, Y. Tomer, S. Slavin, 1995, Scandinavian journal of immunology.

Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine‐based preparative regimen

P. Tsirigotis, M. Aker, S. Slavin, 2006, British journal of haematology.

Second transplantation using allogeneic peripheral blood stem cells in a β‐thalassaemia major patient featuring stable mixed chimaerism

A. Nagler, A. Oppenheim, D. Filon, 1996, British journal of haematology.

Potential Use of Interleukin-6 in Bone Marrow Transplantation: Effects of Recombinant Human Interleukin-6 After Syngeneic and Semiallogeneic Bone Marrow Transplantation in Mice

S. Slavin, M. Revel, T. Givon, 1994 .

Selective CD4+ T-cell depletion does not prevent graft-versus-host disease.

A. Nagler, S. Slavin, R. Or, 1998, Transplantation.

Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation.

S. Slavin, L. Weiss, S. Reich, 1990, Bone marrow transplantation.

The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin

P. Tsirigotis, S. Slavin, R. Or, 2010, Bone Marrow Transplantation.

Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR.

S. Montoto, P. Hari, R. Gale, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP)

J. Esteve, M. Labopin, J. Finke, 2005, Leukemia.

Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells.

E. Fibach, S. Elad, S. Slavin, 2005, Experimental hematology.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Sonali M. Smith, M. Perales, R. Gale, 2016, Blood.

Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.

S. Slavin, T. Prigozhina, G. Elkin, 2008, Experimental hematology.

Total lymphoid irradiation, anti-lymphocyte globulin and Campath 1-G for immunosuppression prior to bone marrow transplantation for aplastic anemia after repeated graft rejection.

J. Mehta, A. Nagler, J. Kapelushnik, 1994, Bone marrow transplantation.

Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation.

A. Nagler, S. Slavin, G. Váradi, 2000, Experimental hematology.

Cancer immunotherapy with alloreactive lymphocytes.

S. Slavin, 2000, The New England journal of medicine.

Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice.

S. Slavin, T. Prigozhina, O. Gurevitch, 1999, Experimental hematology.

A fludarabine-based protocol for bone marrow transplantation in Fanconi’s anemia

A. Nagler, J. Kapelushnik, S. Slavin, 1997, Bone Marrow Transplantation.

Effect of total lymphoid irradiation on natural killer cells and cytotoxic and primed T lymphocytes.

S. Slavin, L. Weiss, 1994, Israel journal of medical sciences.

New strategies for bone marrow transplantation.

S. Slavin, 2000, Current opinion in immunology.

Autologous and Allogenic Stem Cell Transplantation for the Treatment of Autoimmune Diseases as a Potential New Approach

S. Slavin, 1999 .

Induction of Bilateral Transplantation Tolerance to Cellular and Perfused Allografts and Xenografts with Donor Hematopoietic Cells a

S. Slavin, OLGA GUREVITCH, TATIANA PRIGHOZINA, 1998, Annals of the New York Academy of Sciences.

The use of parabiosis for investigating the mechanism of transplantation tolerance in bone marrow chimeras induced by total lymphoid irradiation

S. Slavin, S. Morecki, Ahmed Abulfotooh Eid, 1990, Transplant international : official journal of the European Society for Organ Transplantation.

The use of total lymphoid irradiation (TLI) as immunosuppressive therapy for organ allotransplantation and autoimmune diseases.

Z. Fuks, S. Slavin, 1981, International journal of radiation oncology, biology, physics.

Total Lymphoid Irradiation

J. Najarian, D. Sutherland, R. Simmons, 1980, The Lancet.

Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.

S. Slavin, U. Vourka-Karussis, B. Leshem, 2000, Cytokines, cellular & molecular therapy.

Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients

A. Nagler, Y. Ilan, D. Shouval, 2000, Bone Marrow Transplantation.

Bone marrow transplantation in thalassaemia.

E. Rachmilewitz, S. Slavin, 1986, Bone marrow transplantation.

Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.

Y. Reisner, S. Slavin, L. Weiss, 1994, Journal of immunology.

The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?

S. Slavin, R. Or, L. Weiss, 1990, Bone marrow transplantation.

Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses

M. Zeira, S. Slavin, L. Schuger, 2003, Bone Marrow Transplantation.

Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia

S. Slavin, L. Weiss, S. Nusair, 1996, Cancer Immunology, Immunotherapy.

Lessons from bone marrow transplantation for a victim of a radiological accident with acute radiation syndrome

S. Slavin, I. Resnick, 2005 .

Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.

J. Kasir, S. Slavin, L. Weiss, 2005, Cancer research.

Linomide administration following bone marrow transplantation in mice

Y. Shufaro, S. Slavin, L. Weiss, 2002, Cancer Immunology, Immunotherapy.

Failure of cyclosporine to induce graft-vs-host disease or graft-vs-leukemia after syngeneic bone marrow transplantation in mice.

S. Singhal, J. Mehta, S. Slavin, 1996, Leukemia research.

Control of relapse due to minimal residual disease (MRD) by cell-mediated cytokine-activated immunotherapy in conjunction with bone marrow transplantation.

A. Nagler, S. Slavin, R. Or, 1991, Bailliere's clinical haematology.

Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report

P. Tsirigotis, S. Slavin, R. Or, 2005, Bone Marrow Transplantation.

Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.

A. Nagler, J. Kapelushnik, S. Slavin, 1995, Experimental hematology.

ELEVATED INFLAMMATORY CYTOKINE LEVELS IN BONE MARROW GRAFT REJECTION

V. Barak, I. Kalickman, S. Slavin, 1995, Transplantation.

Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?

J. Kasir, M. Zeira, S. Slavin, 2006, Bone Marrow Transplantation.

Ketotifen therapy in chronic graft‐versus‐host disease (cGVHD): effect on mast cells and fibroblasts

A. Nagler, F. Levi-Schaffer, S. Slavin, 1995, Clinical and experimental immunology.

Long-term effects of splenectomy on immunocompetent cells of adult mice.

S. Strober, S. Slavin, I. Zan‐Bar, 1980, Cellular immunology.

The clinically validated viral superinfection therapy (SIT) platform technology could cure early cases of COVID-19 disease

W. Renz, V. Sandig, P. Chumakov, 2021 .

Effector cells of graft-versus-host disease, host resistance, and the graft-versus-leukemia effect: summary of a workshop on bone marrow transplantation.

H. Deeg, O. Ringdén, S. Slavin, 1987, Transplantation proceedings.

Differential killing of murine B-cell leukemia (BCL1) by photosensitization with merocyanine 540: implications for autologous bone marrow transplantation.

J. Spivak, S. Slavin, L. Weiss, 1989, Bone marrow transplantation.

Lectin separation of nonlymphoid suppressor cells induced by total lymphoid irradiation

S. Slavin, S. Morecki, Marilyn Weigensberg, 1985, European journal of immunology.

Irradiated mononuclear cells express significant in vitro cytotoxic activity: promise for in vivo clinical efficacy of irradiated mismatched donor lymphocytes infusion.

P. Tsirigotis, Violetta Kapsimalli, Ekaterini Psarra, 2014, Immunotherapy.

Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia.

S. Giralt, S. Slavin, A. Carella, 2000, Haematologica.

Prediction by a modified mixed leukocyte reaction assay of graft-versus-host disease and graft rejection after allogeneic bone marrow transplantation.

E. Kedar, C. Brautbar, S. Slavin, 1994, Transplantation.

Bone marrow transplantation in beta-thalassemia major with prevention of graft-vs-host disease.

G. Hale, H. Waldmann, C. Brautbar, 1988, Birth defects original article series.

Cellular Therapy by Non-Myeloablative Stem Cell Transplantation and Immunotherapy of Minimal Residual Disease

A. Nagler, S. Slavin, G. Váradi, 1999 .

Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen

P. Tsirigotis, M. Aker, S. Slavin, 2007, Bone Marrow Transplantation.

Higher than expected transplant-related mortality and relapse following nonmyeloablative stem cell transplantation for lymphoma adversely effects progression free survival.

N. Schmitz, N. Russell, S. Mackinnon, 2000 .

Transplantation tolerance across major histocompatibility barriers after total lymphoid irradiation.

Z. Fuks, D. Sutherland, R. Howard, 1979, Transplantation.

Long-term enzyme replacement therapy in beta-glucuronidase--deficient mice by allogeneic bone marrow transplantation.

Z. Fuks, S. Slavin, S. Morecki, 1982, The Journal of laboratory and clinical medicine.

TRANSMISSION OF BRUCELLOSIS BY BONE MARROW TRANSPLANTATION

S. Slavin, E. Naparstek, C. Block, 1982, The Lancet.

Reduced intensity versus truly nonmyeloablative conditioning for stem-cell transplant recipients.

S. Slavin, 2004, Transplantation.

Transient recovery of endogenous immune function following haploidentical peripheral stem cell transplantation in a patient with severe combined immunodeficiency without evidence of engraftment

J. Kapelushnik, C. Brautbar, S. Slavin, 2000, Acta paediatrica.

Right atrial thrombi are related to indwelling central venous catheter position: insights into time course and possible mechanism of formation.

D Schechter, M S Gotsman, M. Gotsman, 1998, American heart journal.

Non-myeloablative stem cell transplantation for autoimmune diseases

R. Burt, L. Verda, S. Slavin, 2004, Springer Seminars in Immunopathology.

Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study

S. Slavin, S. Morecki, N. Askenasy, 2010, Cancer Immunology, Immunotherapy.

Immunosuppression and tolerance after total lymphoid irradiation (TLI).

Z. Fuks, R. Hoppe, S. Strober, 1980, Transplantation proceedings.

Use of total lymphoid irradiation (TLI) in bone marrow and organ transplantation.

R. Hoppe, S. Strober, H. Kaplan, 1979, Transplantation proceedings.

Transplantation tolerance after total lymphoid irradiation.

Z. Fuks, R. Hoppe, S. Strober, 1979, Transplantation proceedings.

Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation.

Z. Fuks, S. Strober, H. Kaplan, 1976, Science.

IMMUNOSUPPRESSION AND PERMANENT TRANSPLANTATION TOLERANCE ACROSS MAJOR HISTOCOMPATIBILITY BARRIERS FOLLOWING TOTAL LYMPHOID IRRADIATION

Z. Fuks, R. Hoppe, S. Strober, 1979 .

Oxidative stress protection by novel telomerase activators in mesenchymal stem cells derived from healthy and diseased individuals.

A. Gazit, A. Braiman, S. Slavin, 2013, Current molecular medicine.

New insights into the pathophysiology of gastrointestinal graft-versus-host disease using capsule endoscopy.

H. Jacob, S. Slavin, R. Or, 2005, Haematologica.

Serum transcobalamin levels as an early indicator of bone marrow engraftment following transplantation

Z. Fuks, S. Slavin, E. Naparstek, 1983, British journal of haematology.

Immunoglobulins A, G, and M to cytomegalovirus during recurrent infection in recipients of allogeneic bone marrow transplantation.

D. Engelhard, I. Sarov, S. Slavin, 1991, The Journal of infectious diseases.

Clinical Outcomes of Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum Undergoing Autologous HCT: a CIBMTR Retrospective Analysis

N. Ueno, M. Bishop, H. Lazarus, 2012, Bone Marrow Transplantation.

Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders.

E. Kedar, S. Slavin, A. Ackerstein, 1991, Blood.

A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation

S. Elad, S. Slavin, R. Or, 2003, Bone Marrow Transplantation.

CD44 Involvement in Autoimmune Inflammations

E. Turley, D. Karussis, Y. Zick, 2007, Annals of the New York Academy of Sciences.

Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody.

R. Stern, R. Stern, A. Rubinstein, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma.

M. Zeira, S. Slavin, R. Or, 2009, Leukemia research.

Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.

S. Slavin, L. Weiss, U. Vourka-Karussis, 1993, Journal of immunology.

Immunotherapy of cancer with alloreactive lymphocytes.

S. Slavin, Shimon Slavin, 2001, The Lancet. Oncology.

Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes.

S. Slavin, T. Prigozhina, J. Zhu, 1997, Transplantation.

The use of total lymphoid irradiation (TLI) for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematological disorders.

D. Engelhard, C. Brautbar, M. Aker, 1989, Transplantation proceedings.

Adoptive transfer of resistance to Pseudomonas aeruginosa infection by splenocytes and bone marrow cells from BALB/c mice immunized by pseudomonas aeruginosa lectin preparations

S. Slavin, N. Gilboa‐Garber, D. Avichezer, 1989, Infection.

Interstitial pneumonitis after total body irradiation: effect of partial lung shielding

S. Slavin, R. Breuer, R. Or, 1990, British journal of haematology.

malignancies relapsing post BMT (letter; comment) Allogeneic cell therapy: the treatment of choice for all hematologic

A. Nagler, S. Slavin, A. Ackerstein, 2011 .

Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT.

A. Nagler, S. Slavin, R. Or, 1996, Blood.

Monoclonal rat anti-human lymphocyte antibody Campath-1 binds to T and B lymphocytes but effectively lyses only T cells.

Y. Gazitt, S. Slavin, R. Or, 1987, Bone marrow transplantation.

The use of total lymphoid irradiation for allogeneic bone marrow transplantation in animals and man

Z. Fuks, S. Slavin, S. Morecki, 1985, Survey of immunologic research.

Generation of protein-specific and alloantigen-specific suppressor cells following total lymphoid irradiation in mice.

S. Strober, S. Slavin, I. Zan‐Bar, 1979, Transplantation proceedings.

Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT).

A. Nagler, S. Slavin, R. Or, 1992, Leukemia.

New developments in bone marrow transplantation.

A. Nagler, S. Slavin, 1991, Current opinion in oncology.

Induction of cell-mediated IL-2-activated antitumor responses in conjunction with autologous and allogeneic bone marrow transplantation.

A. Nagler, E. Kedar, S. Slavin, 1991, Transplantation proceedings.

Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models.

S. Slavin, S. Morecki, T. Prigozhina, 2002, Experimental hematology.

Reactivity of Human Monoclonal Antibody Campath-1 with Human Leukemia Lymphoma Cell Lines of Varying Maturation.

H. Ben-bassat, Z. Shlomai, S. Slavin, 1990, Leukemia & lymphoma.

Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation.

I. Fabian, S. Slavin, I. Bleiberg, 1991, Experimental hematology.

Improved survival following induction of GVHD following lipopolysaccharide immunization.

S. Slavin, R. Or, L. Weiss, 2006, Experimental hematology.

Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a.

A. Nagler, V. Barak, S. Slavin, 1994, Journal of hematotherapy.

Effect of various cytokine combinations on induction of non-MHC-restricted cytotoxicity.

A. Nagler, M. Pick, S. Slavin, 1993, Lymphokine and cytokine research.

Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-α2a and interleukin-2

A. Nagler, S. Revel-Vilk, M. Pick, 1992, Cancer Immunology, Immunotherapy.

Interleukin-7 induced facilitation of immunological reconstitution of sublethally irradiated mice following treatment with alloreactive spleen cells in a murine model of B-cell leukemia/lymphoma (BCL1)

A. Ben‐Yehuda, S. Slavin, D. Ergas, 2007, Bone Marrow Transplantation.

Minimal residual disease in murine B-cell leukemia (BCL1) detected by PCR.

S. Slavin, L. Weiss, T. Pugatsch, 1993, Leukemia research.

Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma.

A. Nagler, S. Slavin, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Interleukin-7-enhanced cytotoxic T lymphocyte activity after viral infection in marrow transplanted mice

G. Friedman, Z. Zakay‐Rones, A. Ben‐Yehuda, 1997, Bone Marrow Transplantation.

Interleukin 2 regulation following semi-allogeneic bone marrow transplantation in mice

A. Ben‐Yehuda, S. Slavin, R. Or, 2006, Cancer Immunology, Immunotherapy.

Therapeutic potential of recombinant granulocyte-macrophage colony-stimulating factor and interleukin-3 in murine B-cell leukemia.

I. Fabian, S. Slavin, Y. Kletter, 1988, Blood.

Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.

S. Slavin, A. Ackerstein, U. Vourka-Karussis, 1999, Experimental hematology.

Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes

A. Nagler, J. Kapelushnik, M. Aker, 1997 .

IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2.

E. Kedar, S. Slavin, L. Weiss, 1990, Bone marrow transplantation.

Towards Possible Cure of Cancer by Immunotherapy of Minimal Residual Disease Using Intentionally Mismatched Donor Lymphocytes

S. Slavin, 2020 .

Treatment of Leukemia by Alloreactive Lymphocytes and Nonmyeloablative Stem Cell Transplantation

A. Nagler, S. Slavin, R. Or, 2002, Journal of Clinical Immunology.

Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals

A. Nagler, S. Panigrahi, A. Symeonidis, 2001, Cancer Chemotherapy and Pharmacology.

Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.

A. Nagler, M. Aker, S. Slavin, 2001, Reviews in clinical and experimental hematology.

Future strategies in hematopoietic stem cell transplantation for rheumatoid arthritis.

R. Burt, S. Slavin, Y. Oyama, 2001, The Journal of rheumatology. Supplement.

Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia

H. Waldmann, S. Cobbold, S. Slavin, 2005, Cancer Immunology and Immunotherapy.

Toward improvement of therapeutic strategies in leukemia by amplification of the immune responses against leukemia.

I. Hardan, S. Slavin, R. Or, 1990, Haematology and blood transfusion.

Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1.

E. Galun, D. Galili, C. Brautbar, 1985, Advances in experimental medicine and biology.

ANTILEUKEMIC EFFECTS OF ALLOGENEIC BONE MARROW ALLOGRAFTS IN MICE

E. Vitetta, S. Slavin, S. Morecki, 1982 .

A retrospective review of the outcome after second or subsequent allogeneic transplantation.

M. Aker, S. Slavin, R. Or, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation in ovarian cancer—the EBMT experience

D. Blaise, P. Viens, J. Bay, 2010, International journal of cancer.

Allogeneic Cell-Mediated Immunotherapy at the Stage of Minimal Residual Disease following High-Dose Chemotherapy Supported by Autologous Stem Cell Transplantation

S. Slavin, 2005, Acta Haematologica.

Treatment of X‐linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen

M. Ben-Harush, J. Kapelushnik, S. Slavin, 2005, Clinical transplantation.

Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation

S. Slavin, 2004, The Lancet.

Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.

A. Nagler, J. Kapelushnik, S. Slavin, 1996, Clinical transplants.

Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

E. Havrdová, R. Clark, A. Steck, 2006, Multiple sclerosis.

Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT.

A. Oppenheim, S. Slavin, T. Pugatsch, 1996, Bone marrow transplantation.

Time to engraftment following allogeneic stem cell transplantation is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia

S. Elad, S. Slavin, R. Or, 2008, Bone Marrow Transplantation.

Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients

S. Elad, S. Slavin, R. Or, 2004, Bone Marrow Transplantation.

Minitransplants and cell-based therapies for malignant and nonmalignant disorders

A. Nagler, C. Brautbar, M. Aker, 1999 .

Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.

S. Slavin, R. Or, M. Shapira, 2003, Clinical transplants.

Suppression of cell-mediated immune responses after total lymphoid irradiation (TLI). I. Characterization of suppressor cells of the mixed lymphocyte reaction.

Z. Fuks, S. Slavin, S. Morecki, 1984, Journal of immunology.

RHU GM-CSF shortens aplasia duration after ABMT in non-Hodgkin's lymphoma: a randomized placebo-controlled double-blind study.

P. Colombat, N. Gorin, T. Philip, 1991, Bone marrow transplantation.

Deletion of donor-reactive cells as a new conditioning regimen for allogeneic bone marrow transplantation.

S. Slavin, T. Prigozhina, G. Elkin, 2007, Transplantation proceedings.

Commentary (Slavin): Nonmyeloablative Preparative Regimens for Allogeneic Hematopoietic Transplantation

S. Slavin, 2003 .

Maternal-fetal relationship, natural chimerism and bilateral transplantation tolerance as the basis for non-myeloablative stem cell transplantation

S. Slavin, 2002, International journal of hematology.

[Bone marrow transplantation].

A. Nagler, G. Vardi, S. Slavin, 1995, Harefuah.

Anti-rIL-2 receptor antibodies and marrow aplasia

S. Slavin, 2003 .

Successful T cell-depleted allogeneic bone marrow transplantation in a child with recurrent multiple extramedullary plasmacytomas.

J. Mehta, S. Slavin, R. Or, 1992, Bone marrow transplantation.

Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases.

A. Nagler, S. Panigrahi, S. Slavin, 2001, Critical reviews in oncology/hematology.

Transplant of ex vivo incubated bone marrow with rIL -7 for the enhancement of immuno-hematopoietic reconstitution

S. Slavin, R. Or, A. Abdul-Hai, 2015, Leukemia & lymphoma.

Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations

S. Pakakasama, S. Slavin, S. Hongeng, 2012, Pediatric transplantation.

The role of the spleen in tumor growth kinetics of the murine B cell leukemia (BCL1).

S. Slavin, S. Morecki, L. Weiss, 1980, Journal of immunology.

Synthetic, Non-Natural Analogs of Ceramide Elevate Cellular Ceramide, Inducing Apoptotic Death to Prostate Cancer Cells and Eradicating Tumors in Mice

S. Gatt, A. Dagan, S. Slavin, 2010, Cancer investigation.

Ex vivo expansion of megakaryocyte precursors by preincubation of marrow allografts with interleukin-3 and granulocyte-macrophage colony-stimulating factor in vitro.

A. Nagler, A. Eldor, V. Deutsch, 1995, Experimental hematology.

Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study.

D. Raveh, A. Nagler, A. Simhon, 1996, Transplantation.

Induction of transplantation tolerance by intraportal injection of allogeneic bone marrow cells

S. Slavin, S. Morecki, Ahmed Abulfotooh Eid, 1988, Transplant international : official journal of the European Society for Organ Transplantation.

Induction of transplantation tolerance by intraportal injection of allogeneic bone marrow cells: Possible implications for intrauterine bone marrow transplantation across major histocompatibility barriers

A. Eid, S. Slavin, S. Morecki, 1988 .

Effect of recombinant human manganese superoxide dismutase on radiosensitivity of murine B cell leukemia (BCL1) cells.

S. Slavin, L. Weiss, S. Stern, 1993, Leukemia & lymphoma.

The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice.

M. Neeman, L. Benjamin, R. Abramovitch, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Multiformic modulation of endotoxin effects by linomide.

M. Gelderman, I. Gery, G. Reed, 1999, Clinical immunology.

Resistance to mycobacteria in mice treated with fractionated total lymphoid irradiation (TLI) and in mice reconstituted with allogenic bone marrow cells following radiotherapy.

N. Mor, S. Slavin, S. Morecki, 1985, International journal of radiation oncology, biology, physics.

Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy.

D. Gozal, Z. Vered, E. Kaluski, 2005, American heart journal.

Enrichment for GM-CFU from human bone marrow using Sambucus nigra agglutinin: potential application to bone marrow transplantation.

S. Slavin, D. Manor, M. Mumcuoglu, 1986, Experimental hematology.

Long-Term Safety and Efficacy of Gene Therapyfor Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency

S. Galimberti, M. Roncarolo, M. Eibl, 2009 .

Hemopoietic activity in bone marrow chimeras prepared with total lymphoid irradiation (TLI).

S. Slavin, H. Seidel, 1982, Experimental hematology.

Neuroprotection in multiple sclerosis

D. Karussis, N. Grigoriadis, O. Abramsky, 2006, Clinical Neurology and Neurosurgery.

Mechanisms of transplantation tolerance to allogeneic bone marrow cells following total lymphoid irradiation (TLI).

S. Strober, S. Slavin, 1980, Haematology and blood transfusion.

Effect of total lymphoid irradiation (TLI) on the primary and secondary antibody response to sheep red blood cells.

S. Strober, S. Slavin, I. Zan‐Bar, 1979, Cellular immunology.

Allogeneic cell therapy as potential cure of hematologic malignancies

S. Slavin, 2020 .

Shifting Towards Better Immunotherapy Rather Than More Intensive Chemoradiotherapy Using a Non-Myeloablative Approach in Patients with Leukemia

A. Nagler, S. Panigrahi, S. Slavin, 2001 .

Nonmyeloablative Allogeneic Stem Cell Transplantation: Towards Improving Efficacy of Immunotherapy Instead of Myeloablative Chemoradiotherapy

A. Nagler, R. Ben-Yosef, S. Slavin, 2000 .

In vivo CAMPATH‐1 monoclonal antibodies: A novel mode of therapy for acute graft‐versus‐host disease

A. Nagler, S. Slavin, G. Váradi, 1996, American journal of hematology.

Vivo in Inhibition of a von Hippel-Lindau Pheochromocytoma Treatment with Halofuginone Results in Marked Growth

M. Neeman, A. Nagler, M. Pines, 2003 .

Obstructive jaundice associated with carcinoma of the prostate.

I. S. Levij, M. Eliakim, S. Slavin, 1975, Israel journal of medical sciences.

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies

T. Bakács, C. Kerepesi, R. Moss, 2020, Cancer Immunology, Immunotherapy.

Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.

M. Glikson, G. Hale, S. Slavin, 1987, Transplantation proceedings.

A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients.

P. Tsirigotis, S. Slavin, B. Gesundheit, 2006, Haematologica.

Tumorigenicity and immunogenicity in a murine model of B-cell leukemia/lymphoma (BCL1).

A. Nagler, Y. Moshel, Z. Zakay‐Rones, 1998, Leukemia research.

380: Alefacept Treatment for Chronic Extensive Graft Versus Host Disease

P. Tsirigotis, M. Aker, S. Slavin, 2008 .

Immune response to polio vaccination in bone marrow transplant recipients.

R. Handsher, D. Engelhard, I. Hardan, 1991, Bone marrow transplantation.

Felty ' s syndrome . granulocytopenia in a case of Cell mediated autoimmune

S. Slavin, M. Liang, 2022 .

A 2‐DAY MLR PROCEDURE FOR MARROW DONOR SELECTION FOR ALLOGENEIC BONE MARROW TRANSPLANTATION

E. Kedar, C. Brautbar, S. Slavin, 1993, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

Inhibition of Tumors in Mice Models by a Synthetic Ceramide-analog AD2725

M. Zeira, S. Gatt, A. Dagan, 2016 .

Cell-mediated immunity in idiopathic autoimmune haemolytic disease.

E. Rachmilewitz, S. Slavin, M. Aker, 1975, Clinical and experimental immunology.

Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL

Wei Jiang, C. Brodie, S. Slavin, 2016, Stem Cell Research & Therapy.

Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.

A. Nagler, V. Kravtsov, I. Fabian, 1994, Leukemia.

Rhinolalia as a presenting sign of pneumomediastinum complicating post peripheral blood stem cell transplantation bronchiolitis obliterans

S. Elad, S. Slavin, U. Laxer, 2003, American journal of hematology.

Low‐dose γ‐irradiation promotes survival of injured neurons in the central nervous system via homeostasis‐driven proliferation of T cells

E. Hauben, J. Kipnis, S. Slavin, 2004, The European journal of neuroscience.

Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment.

A. Clark, H. Okamoto, S. Slavin, 1998, Endocrinology.

The effect of pegylated antisense acetylcholinesterase on hematopoiesis.

S. Slavin, L. Weiss, J. Katzhendler, 2003, Oligonucleotides.

Kidney allograft survival in dogs treated with total lymphoid irradiation.

J. Najarian, D. Sutherland, R. Howard, 1981, Annals of Surgery.

Transplantation of bone marrow in outbred dogs without graft-versus-host disease using total lymphoid irradiation.

R. Hoppe, S. Strober, H. Kaplan, 1979, Transplantation.

Long-term clinical studies of high-risk renal retransplant recipients given total lymphoid irradiation.

J. Najarian, D. Sutherland, D. Kaufman, 1989, Transplantation proceedings.

Protective role of bone marrow cells in controlling alloreactivity.

S. Slavin, 2003, Transplantation.

Natural cell-mediated cytotoxicity in mice treated with total lymphoid irradiation (TL1).

E. Kedar, S. Slavin, M. Weigensberg, 1982, Cellular immunology.

Cytogenetic analysis of the spontaneous murine B-cell leukemia (BCL1).

S. Slavin, R. Voss, G. Maftzir, 1980, Leukemia research.

Functional clonal deletion versus suppressor cell-induced transplantation tolerance in chimeras prepared with a short course of total-lymphoid irradiation.

S. Slavin, S. Morecki, M. Weigensberg, 1986, Transplantation.

The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation

A. Nagler, D. Niederwieser, T. Witte, 2008, Bone Marrow Transplantation.

Interstitial pneumonitis in T cell-depleted bone marrow transplantation.

D. Engelhard, S. Slavin, R. Breuer, 1988, Bone marrow transplantation.

Effect of Linomide on adhesion molecules, TNF-α, nitrogen oxide, and cell adhesion

R. Hershkoviz, O. Lider, S. Slavin, 2005 .

In vitro and in vivo cytokine-induced facilitation of immunohematopoietic reconstitution in mice undergoing bone marrow transplantation.

A. Landesberg, E. Kedar, S. Slavin, 1988, Bone marrow transplantation.

Immunomodulation of autoimmunity by linomide.

D. Karussis, D. Lehmann, H. Ovadia, 1995, Israel journal of medical sciences.

Continuous intravenous administration of rmGM-CSF enhances immune as well as hematopoietic reconstitution following syngeneic bone marrow transplantation in mice.

J. Greenberger, M. Ohana, S. Slavin, 1993, Experimental Hematology.

Marrow transplantation in multiple myeloma.

J. Mehta, A. Nagler, S. Slavin, 1992, New England Journal of Medicine.

The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z).

E. Kedar, S. Slavin, M. Mumcuoglu, 1989, Bone marrow transplantation.

Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the European Group for Blood and Marrow Transplantation (EBMT).

M. Labopin, D. Blaise, M. Mohty, 2005 .

New approaches for control of anti-self reactivity in type 1 diabetes mellitus and transplantation of pancreatic islets

S. Slavin, D. Gross, L. Weiss, 1999, Journal of Molecular Medicine.

A partial characterization of suppressor cells in the spleens of mice conditioned with fractionated total lymphoid irradiation (TLI).

E. Vitetta, S. Slavin, R. May, 1983, Journal of Immunology.

Spinal epidural lipomatosis following haploidentical allogeneic bone marrow transplantation for non‐Hodgkin lymphoma

J. Gomori, S. Slavin, R. Or, 2004, Clinical transplantation.

A lupus-like syndrome due to lbuprofen hypersensitivity.

Y. Levo, M. Eliakim, S. Slavin, 1980, Journal of Rheumatology.

Non-myeloablative allogeneic stem cell transplantation for the treatment of patients with chronic myeloid leukemia

A. Nagler, M. Aker, S. Slavin, 2000 .

The importance of patient selection in nonmyeloablative stem cell transplant (NMSCT) for acute and chronic leukaemia, myelodysplastic syndrome, and myeloma

G. Gahrton, S. Mackinnon, F. Frassoni, 2000 .

Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation.

S. Slavin, S. Morecki, R. Or, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bacterial pneumonia in recipients of bone marrow transplantation. A five-year prospective study.

I. Lossos, A. Nagler, M. Shapiro, 1995, Transplantation.

Adoptive transfer of immunity to hepatitis B virus after T cell–depleted allogeneic bone marrow transplantation

A. Nagler, Y. Ilan, S. Slavin, 1993, Hepatology.

A case of adrenogenital syndrome with aberrant 11beta-hydroxylation.

S. Slavin, I. Maschler, I. Chowers, 1977, Acta endocrinologica.

Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients.

A. Nagler, D. Engelhard, A. Morag, 1993, Bone marrow transplantation.

IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.

S. Yarkoni, S. Slavin, N. Askenasy, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunoregulation of GVHD by triggering the innate immune system with CpG

S. Slavin, S. Morecki, 2009, Expert review of hematology.

Immunotherapy in conjunction with autologous bone marrow transplantation.

S. Slavin, L. Weiss, E. Naparstek, 1990, Bone Marrow Transplantation.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Sonali M. Smith, M. Perales, R. Gale, 2016, Blood.

Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis.

T. Ben-Hur, D. Karussis, N. Grigoriadis, 2008, Archives of neurology.

Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.

J. Bulte, J. Gomori, T. Ben-Hur, 2010, Archives of neurology.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

J. Vose, Sonali M. Smith, P. Hari, 2012, Blood.